Earnings
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
COSCIENS Sheds German Subsidiaries and $11M Pension Liability as Cash Burn Outpaces Declining Revenue
Executive Summary
- COSCIENS reported Q4 2025 net loss of $2.2M and FY 2025 net loss of $10.4M, reflecting YoY reductions of $4.5M and $4.9M respectively, driven by lower impairment, R&D, and SG&A expenses.
- The company formally filed an insolvency application on March 23, 2026, for its German subsidiaries (Aeterna Zentaris GmbH and Zentaris IVF GmbH), ceasing all funding to these entities.
- Management expects the insolvency to generate ~$1.9M in annualized cost savings and permanently remove associated liabilities, most notably an $11.0M unfunded pension obligation, from future consolidated financials.
- Cash and cash equivalents stood at $7.3M as of December 31, 2025, down from $8.5M reported in September 2025.
- Revenue declined to $1.8M in Q4 and $7.5M for FY 2025, pressured by lower pharmaceutical and active-ingredient sales.
- The company plans to seek shareholder approval in June 2026 to suspend U.S. Exchange Act reporting while maintaining its TSX and OTC listing status.
Material Impact
- The March 25 release is a direct financial and operational follow-up to the March 5 strategic update announcing the German subsidiary insolvency. The market had already priced in the strategic retreat.
- The removal of the $11.0M pension liability is a tangible balance sheet improvement that eliminates a severe long-term overhang, but it comes at the cost of surrendering Macrilen rights and exiting a core pharmaceutical segment.
- Despite aggressive zero-based budgeting and headcount reductions, the company continues to burn cash at a rate that outpaces its declining revenue base. The $1.2M cash decline over Q4 2025 indicates a quarterly burn of roughly $2.5M to $3.0M, leaving a runway of approximately 9 to 12 months without additional capital.
- The news confirms a managed contraction rather than a growth pivot. It is positive for survival but does not alter the fundamental lack of near-term revenue catalysts.
CSCI · Price
Company Overview
- COSCIENS Biopharma operates in two primary segments: natural plant-based active ingredients (oat-derived compounds like beta glucan, avenanthramides, oat oil) and pharmaceutical/diagnostic products.
- The former flagship project, Macrilen (macimorelin), an FDA/EMA-approved oral diagnostic test for adult growth hormone deficiency, has been effectively abandoned following failed Phase 3 pediatric trials and the subsequent German subsidiary insolvency.
- The company is pivoting toward its active-ingredients business and PGX (Pressurized Gas eXpanded) biocomposite technology, while winding down the JuventeDC cosmeceutical line due to poor e-commerce traction.
More from COSCIENS BIOPHARMA INC
Jun 18, 2026 · 08:30